Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review. (https://dx.doi.org/10.3390/nu15143265)
Short-chain fatty and carboxylic acid changes associated with fecal microbiota transplant communally influence microglial inflammation. (https://dx.doi.org/10.1016/j.heliyon.2023.e16908)
Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. (https://dx.doi.org/10.1016/S1473-3099(23)00047-6)
[Fecal Microbiota Transplants in the Context of (Child and Adolescent) Psychiatric Disorders]. (https://dx.doi.org/10.1024/1422-4917/a000928)
Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. (https://dx.doi.org/10.3390/ijms24043074)
The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects. (https://dx.doi.org/10.3390/biomedicines11020426)
The Role of Fecal Microbiota Transplantation in the Treatment of Neurodegenerative Diseases: A Review. (https://dx.doi.org/10.3390/ijms24021001)
Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3. (https://dx.doi.org/10.1021/acsinfecdis.2c00445)
Metabolic Phenotyping Study of Mouse Brain Following Microbiome Disruption by C.difficile Colonization. (https://dx.doi.org/10.3390/metabo12111039)
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. (https://dx.doi.org/10.1007/s40265-022-01797-x)
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial. (https://dx.doi.org/10.1001/jama.2022.16476)
Ion Exchange Conversion of Na-Birnessite to Mg-Buserite for Enhanced and Preferential Cu(2+) Removal via Hybrid Capacitive Deionization. (https://dx.doi.org/10.1021/acsami.2c13086)
Clostridioides difficile and neurological disorders: New perspectives. (https://dx.doi.org/10.3389/fnins.2022.946601)
Pain and Opioid-Induced Gut Microbial Dysbiosis. (https://dx.doi.org/10.3390/biomedicines10081815)
Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection. (https://dx.doi.org/10.18632/aging.204230)
Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases. (https://dx.doi.org/10.3390/jcm11144119)
An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases. (https://dx.doi.org/10.1111/jgh.15731)
The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. (https://dx.doi.org/10.1016/j.lanepe.2021.100181)
Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. (https://dx.doi.org/10.1080/19490976.2021.1979878)
Cognitive function improvement after fecal microbiota transplantation in Alzheimer's dementia patient: a case report. (https://dx.doi.org/10.1080/03007995.2021.1957807)
